NK CellTech, a Shanghai-based developer of natural killer (NK) cell therapies, has announced that it has received clinical clearance from China’s National Medical Products Administration (NMPA) for its proprietary genetically modified NK-cell therapy. This marks a significant milestone as the company’s molecule is set to be assessed as a treatment for a variety of solid tumor types.
NK042, the first of its kind to enter clinical trials in China, is a universal genetically modified NK cell injection sourced from allogeneic peripheral blood. This innovative therapy holds the potential to treat not only solid tumors and hematological tumors but also non-tumor related diseases, showcasing the broad applicability of this cutting-edge approach.- Flcube.com
